GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » 3-Year Revenue Growth Rate

Heidelberg Pharma AG (XTER:HPHA) 3-Year Revenue Growth Rate : -9.30% (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG 3-Year Revenue Growth Rate?

Heidelberg Pharma AG's Revenue per Share for the three months ended in Feb. 2024 was €0.03.

During the past 12 months, Heidelberg Pharma AG's average Revenue per Share Growth Rate was -63.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -9.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 8.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Heidelberg Pharma AG was 33.40% per year. The lowest was -59.20% per year. And the median was -19.60% per year.


Competitive Comparison of Heidelberg Pharma AG's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Heidelberg Pharma AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's 3-Year Revenue Growth Rate falls into.



Heidelberg Pharma AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Heidelberg Pharma AG  (XTER:HPHA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Heidelberg Pharma AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines